Ciclidon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciclidon

Property Description
Active Ingredients Desogestrel, Ethinyl Estradiol
Form Tablet (Oral Dosage Form)
Pharmacological Class Hormonal Contraceptive (Combined Oral Contraceptive)
Common Use Systemic Contraception (Prevention of Pregnancy)
Origin Synthetic (Steroidal Components)

What Type of Medicine is Ciclidon?

Ciclidon is classified as a Combined Oral Contraceptive (COC), placing it within the broader Hormonal Contraceptive pharmacological class, a category recognized for its efficacy in reproductive management. This preparation is a synthetic, prescription-only medication designed for systemic administration via the oral route. Its primary purpose is to provide systemic contraception by acting on the female reproductive system to prevent pregnancy, often used by women seeking predictable, long-term control over their fertility.

Composition and Form: Synthetic Hormones

The active ingredients of Ciclidon are the synthetic steroidal components Desogestrel and Ethinyl Estradiol. Desogestrel is recognized as a third-generation progestin, a characteristic differentiating it structurally and pharmacologically from older progestogen types. Ethinyl Estradiol is a synthetic derivative of the natural hormone estradiol. Ciclidon is a definitive Combination Product because it contains both an estrogen and a progestin, delivered in the standard Oral Dosage Form of a tablet. Other common products containing this specific Desogestrel/Ethinyl Estradiol combination include Ortho-Cept and Desogen.

Primary Role of the Combination Product

The fundamental role of Ciclidon is based on its combined hormonal action, which manages the reproductive cycle to ensure the prevention of pregnancy. This purpose is achieved through the coordinated influence of its two hormone classes, which collectively suppress the critical processes that lead to conception. The combination product design utilizes the synergistic effects of both estrogen and progestin, establishing a multi-level barrier against conception through comprehensive endocrine regulation.

Regulatory References

  1. MedlinePlus Drug Information: Ethinyl Estradiol and Desogestrel

What side effects are possible with Ciclidon?

The safety characteristics of Ciclidon, a Combined Oral Contraceptive containing Desogestrel and Ethinyl Estradiol, are documented in regulatory labeling by classification, system-organ class, and seriousness. This information is based strictly on government health authority documents.

Established Serious Adverse Reactions

A primary established safety concern is an increased risk of thromboembolic and thrombotic disorders, which primarily affect the vascular system. These serious adverse reactions include Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism, including Stroke and Myocardial Infarction. The risk of these events is documented as highest during the first year of use and upon restarting the medication after a break of four weeks or longer. Regulatory documents also note an association with rare occurrences of hepatic neoplasia (benign liver tumors) and gallbladder disease.

Frequency-Classified Systemic Effects

Adverse reactions are formally grouped by frequency. Officially documented Common Adverse Reactions (occurring in 1% to 10% of users) often affect the gastrointestinal, nervous, and psychiatric systems, including nausea, abdominal pain, headache, dizziness, and depressed mood. Uncommon Adverse Reactions (occurring in 0.1% to 1% of users) include vomiting, fluid retention, migraine, nervousness, and dermatological effects such as rash or acne. Changes in the vaginal bleeding pattern, such as breakthrough bleeding or spotting, are noted as common, especially during the first three months of treatment initiation.

Population and Contextual Safety Notes

Specific safety considerations are defined for certain situations. The official label notes a substantially increased risk of serious cardiovascular events for smokers aged 35 and older. Furthermore, safety constraints require the medication to be discontinued before and after elective surgery or prolonged immobilization to mitigate thromboembolism risk. It is also a mandated safety note that this product offers no protection against HIV infection or other sexually transmitted diseases.

Overdose and Emergency Response

Official Overdose Manifestations

The overdose profile for Ciclidon (Desogestrel/Ethinyl Estradiol) is based on official reports following the acute ingestion of high quantities of combined hormonal contraceptive tablets. Documented clinical manifestations primarily involve the gastrointestinal and reproductive systems. These typically include nausea and vomiting.

A frequently reported manifestation is withdrawal bleeding (vaginal bleeding), which occurs due to the abrupt hormonal shift following overexposure. Regulatory documentation indicates that no serious acute effects are generally expected following a large, acute ingestion of this medication type.

Emergency Actions and Required Management

Immediate action is required in the event of a suspected overdose. Regulatory guidance mandates that you seek immediate medical attention or contact a Poison Control Center for specific guidance on next steps.

There is no specific antidote known for an overdose involving these synthetic steroid hormones, as stated in the official labels. Consequently, the required management procedure is strictly confined to providing symptomatic and supportive treatment based on the patient's clinical presentation. Hospital monitoring may be required to observe the patient's condition.

Population-Specific Considerations

A key consideration noted in official documentation is the possibility of withdrawal bleeding in females of any age, including prepubescent girls, following accidental ingestion.

Therapeutic Uses of Ciclidon

What Ciclidon Treats: Main Uses and Benefits

Ciclidon is applied across distinct therapeutic domains, including its primary role in fertility management and its role in offering supportive benefits for various symptom-driven presentations. Such medications are utilized for both contraception and the management of certain gynecologic and dermatologic conditions.

Systemic Contraception and Symptom Support

Ciclidon is generally used to provide pregnancy prevention for adult women seeking predictable, long-term control over their fertility. This primary focus may assist patients with maintaining functional stability in their planning. It is also commonly used in situations that involve increased discomfort related to the menstrual cycle. Indications include the management of symptoms related to physical discomfort, such as heavy menstrual bleeding (menorrhagia), symptoms of increased muscular activity (dysmenorrhea), and symptomatic relief for acne vulgaris.

Supportive Care for Endocrine-Sensitive Conditions

This product is commonly used across conditions presenting with episodic or fluctuating manifestations linked to systemic imbalance. It is applied when symptomatic relief for conditions like acne is appropriate. This supportive use helps manage symptoms related to systemic imbalance (skin symptoms) and may be part of symptomatic management in situations where functional ovarian cysts are a concern. This contributes to easing the overall symptom load.


Quick Fact: Supports management of symptoms that interfere with daily functioning.

Regulatory References

  1. NIH StatPearls review on Oral Contraceptive Pills

Eligibility and Restrictions for Use

Eligibility for Ciclidon

Ciclidon is primarily for use by women of reproductive age, including post-menarcheal adolescents. The medicine is subject to strict regulatory criteria defining eligibility based on a risk profile associated with its combined hormonal composition.

Scope Regulatory Statement
Allowed Population Women of reproductive potential, including post-menarcheal adolescents, for pregnancy prevention.
Not Recommended Breastfeeding women, particularly within the first six months postpartum. Women over 65 years of age (use is not indicated for the elderly).

Ciclidon is contraindicated and must not be used in women presenting with certain conditions, most notably those related to vascular health and hormone-sensitive diseases.

Absolute Contraindications
Current or history of Arterial or Venous Thromboembolism (DVT, PE, Stroke, MI).
Women over 35 years of age who smoke.
Known or suspected breast cancer or other estrogen-dependent tumors.
Known or suspected pregnancy.
Severe Hepatic Disease (active or history, if liver function is abnormal).
Severe Hypertension or Diabetes Mellitus with vascular symptoms.

The medicine must also be discontinued at least four weeks before and for two weeks after major surgery or during prolonged immobilization due to the associated increase in thromboembolic risk.

What should I know about interactions with other medicines?

Ciclidon Interactions with other medicines and products

The interaction profile of Ciclidon is primarily structured around its metabolism by specific liver enzymes and the resulting potential for increased systemic exposure when combined with certain medicines.

Documented Interaction Categories

Category Practical Regulatory Implication
Potent CYP3A4 Inhibitors Co-administration is generally discouraged or requires close monitoring for signs of increased systemic effect.
Desmopressin Co-administration is a contraindication due to a known risk of low blood sodium (hyponatremia).
Other Corticosteroids Use with caution; may increase the overall systemic effect and risk of adrenal suppression.

Specific Interacting Medicines and Substances

Interacting medicines (examples listed in official labels):

  • Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) such as ketoconazole, ritonavir, itraconazole, and clarithromycin.
  • Desmopressin (a specific combination to be avoided).

Mechanism of Interaction: Ciclidon's active component is extensively metabolized by the CYP3A4 enzyme system. Concomitant use with potent CYP3A4 inhibitors prevents this breakdown, leading to significantly increased blood levels of the active component and a heightened risk of systemic adverse effects.

Interaction-Related Constraints

  • High-Level Classification: The use of Ciclidon with Desmopressin is classified as a combination to avoid or use with extreme caution based on the risk of severe hyponatremia.
  • Systemic Risk Constraint: Caution is required when combining Ciclidon with other corticosteroids, including topical or oral forms, as the combined systemic exposure may exceed acceptable limits and lead to a higher risk of HPA axis suppression.

This interaction structure establishes that the primary risk is pharmacokinetic, involving the CYP3A4 pathway, while a specific pharmacodynamic interaction with Desmopressin represents a major safety constraint. Due to the rapid conversion of Ciclidon to its active form, the potential for enzyme-mediated interaction with CYP3A4 inhibitors is considered clinically significant.

Mechanism of Action

How Ciclidon Works: Mechanism of Action

Ciclidon's primary action is the inhibition of L-type voltage-dependent calcium channels (CaV 1.2) located on the membranes of vascular smooth muscle cells. By physically blocking these channels, Ciclidon restricts the influx of extracellular calcium ions (Ca^2+), which are fundamental requirements for initiating the contraction cascade within the vessel wall.

This molecular event disrupts the intracellular signal transduction cascade responsible for muscle contraction. Specifically, the reduced availability of intracellular Ca^2+ prevents the activation of Myosin Light Chain Kinase (MLCK), which leads directly to the relaxation of the smooth muscle fibers.

The resulting physiological effect is a modulation of peripheral vascular tone, causing vasodilation in arterioles and small arteries. This mechanical change leads to a systemic decrease in vascular resistance and increases blood flow and oxygen supply throughout the microcirculation, which contributes to the observed physiological effects of the compound.

Dosage and Administration Information

How to Use Ciclidon

Ciclidon (Desogestrel/Ethinyl Estradiol) is a Combined Oral Contraceptive administered strictly via the oral route as a tablet. The medicine is utilized according to a fixed, recurring 28-day cyclic regimen structured around a daily dosing requirement.

The standard regimen dictates that one tablet is taken once daily at approximately the same time each day, regardless of food intake. The typical cycle consists of 21 consecutive days of active hormone tablets, followed by a 7-day tablet-free or placebo interval. The 28-day pattern is repeated continuously.

Standard Administration Protocols

Procedural Element General Protocol
Starting Regimen Initiation follows a Day 1 Start (first day of menses) or a Sunday Start protocol.
Missed Dose Rule If a single active tablet is missed, the last missed tablet is taken as soon as it is remembered, even if this means taking two tablets in one day.
Initial Adherence When starting the regimen, particularly if not using the Day 1 Start, the protocol includes the concurrent use of a barrier method for the initial 7 days of tablet intake.
Age Group Use Postpubertal adolescents follow the identical dosing and administration schedule as adults.

This structured approach is used for maintaining the integrity of the cyclic hormonal suppression. The administration method follows these protocols, which define both the frequency and the timing of tablet ingestion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ciclidon

Evidence for Systemic Contraception (Prevention of Pregnancy)

Research evaluating Ciclidon in the context of pregnancy prevention includes pivotal efficacy trials (Randomized Controlled Trials) and post-marketing analyses in healthy adult and post-menarche adolescent females. The primary outcome measured in these studies was the contraceptive outcome metric, the Pearl Index (a measure of unintended pregnancies), and studies also monitored cycle regularity and the suppression of ovulation.

Findings describe patterns observed over intermediate-term follow-up periods, typically ranging from 6 to 18 menstrual cycles. The research consistently notes that measured outcomes are conditional on consistent and strict adherence to the prescribed regimen. The study results reflect the specific conditions under which they were conducted.


Evidence for Menstrual Symptom Management

Studies have explored Ciclidon in the context of supportive management for gynecologic symptoms. For outcomes related to Primary Dysmenorrhea (menstrual discomfort), research utilized short-term RCTs to monitor patient-reported outcomes describing perceived discomfort, such as pain severity and cramping symptoms. For Cycle Control, comparative studies examined outcomes related to systemic imbalance, including the consistency of cycle regularity and unscheduled bleeding.

Follow-up durations were limited for some symptom-specific trials (typically 4–6 cycles). Data show patterns related to cycle control were typically monitored as secondary outcomes in studies primarily focused on contraception, reflecting a gap in dedicated long-term symptom research.


Evidence for Symptomatic Acne Relief

Comparative RCTs and systematic reviews have evaluated Ciclidon for patient-reported outcomes in post-menarchal women presenting with mild to moderate facial acne vulgaris. Measured outcomes included total acne lesion counts and metrics for skin condition based on patient feedback. Research describes observed patterns when compared to only some other hormonal formulations, indicating a research gap in comprehensive comparisons.


Overall Research Context

Ciclidon was studied for its use in healthy adult and adolescent females. Specific research examined patient-reported outcomes in post-menarchal women presenting with conditions studied, such as mild to moderate acne vulgaris or primary dysmenorrhea. Data for certain groups, such as those with pre-existing chronic health conditions, remain insufficient. Evidence highlights that long-term effects extending beyond typical trial periods are not fully established across all indications. Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Ciclidon (FAQ)

Q: Is Ciclidon typically used for short-term or chronic conditions?

Ciclidon is a Combined Oral Contraceptive indicated for the prevention of pregnancy. Official regulatory documents describe a continuous, long-term approach for this approved use, following a fixed 28-day cyclic regimen over extended periods.


Q: What is the generally accepted duration of time before Ciclidon starts working?

Official administration instructions advise that full contraceptive protection is not immediate when starting the regimen. Therefore, official labels advise the concurrent use of a barrier method during the initial 7 days of active tablet intake in the first cycle.


Q: What official information is available about Ciclidon and liver function?

Official drug labels state that Ciclidon is contraindicated (must not be used) in individuals with active or a history of severe hepatic disease. Regulatory documents also note that rare occurrences of hepatic neoplasia (benign liver tumors) are listed among the serious potential adverse reactions.


Q: Is it mentioned in the patient information that Ciclidon can cause sleep disturbances?

Patient information materials indicate that difficulties in sleeping (insomnia) are listed as a possible side effect. Fatigue is also noted as a reported systemic effect in the adverse reaction profiles available in the official documentation.


Q: What is the risk profile of Ciclidon for people with a history of heart problems?

Ciclidon is contraindicated for those with a history of blood clots (arterial or venous thromboembolism), ischemic heart disease, or uncontrolled high blood pressure. Official warnings highlight that the risk of severe cardiovascular events is substantially increased for smokers aged 35 years or older.


Q: What specific warnings exist regarding stopping Ciclidon use suddenly?

Upon discontinuation of the medication, the contraceptive effect is quickly reversed, and fertility may return immediately. Furthermore, official safety constraints define conditions where the medication must be discontinued (before and after major surgery or prolonged immobilization) to mitigate the risk of blood clots.


Q: What over-the-counter medicines are known to potentially interact with Ciclidon?

Interactions are possible with certain over-the-counter products that affect the liver's CYP3A4 enzyme system, which breaks down the active components of Ciclidon. The scope of potential drug-drug interactions is described in the official prescribing information.


Q: What common food or beverage is officially noted to interact with Ciclidon?

Regulatory documents specifically note that grapefruit or grapefruit juice may potentially interact with the estrogen component of the medicine. The official guidance recommends stability in the amount of grapefruit intake while using this medication.


Q: Do any specific classes of antidepressant medications interact with Ciclidon?

Interactions with certain antidepressant medications are documented in the official prescribing information. Detailed information on these interactions is available in the official prescribing documentation, which lists specific drug-drug concerns.


Q: What does official guidance say about using herbal supplements with Ciclidon?

Official guidance specifically notes the herbal supplement St. John's Wort. St. John's Wort is known to potentially reduce the contraceptive effectiveness of this class of medicine and is typically recommended to be avoided as a result.


Q: Can Ciclidon be used by people who have existing kidney issues, according to official data?

Official information indicates that caution is warranted for people with existing kidney disease. The official label notes potential for increased systemic exposure, which may relate to the elimination of the drug’s components.


Q: Are there any contraindications listed for Ciclidon related to mental health conditions?

While there is no absolute contraindication based solely on mental health, the medication has been associated with a potential increase in depressed mood as a common adverse reaction. Regulatory documents include a precautionary statement for monitoring patients with a history of depression.


Q: Is Ciclidon a controlled substance in any major jurisdiction?

Ciclidon is classified as a prescription-only medication. Official documents confirm that, as a Combined Oral Contraceptive, it is not classified as a controlled substance under major regulatory frameworks.


Q: What are the official guidelines for recognizing an allergic reaction to Ciclidon?

Official safety documentation describes conditions warranting immediate medical attention, such as signs of a severe allergic reaction. These symptoms may include sudden, large swelling of the face, throat, or tongue, difficulty breathing, or a severe, spreading skin rash.


Q: Does Ciclidon require regular blood tests or monitoring during treatment?

Official guidance defines required monitoring protocols while using this medication. These protocols may include checking blood pressure, along with routine Pap smears and breast exams.


Q: What is the scientific consensus on the long-term safety of Ciclidon?

Regulatory reviews indicate that long-term safety data are primarily based on studies conducted over intermediate periods, typically 6 to 18 menstrual cycles. Evidence confirms that effects extending beyond these trial periods are not fully established across all approved indications.


Q: Is Ciclidon effective for all patients who have the condition it treats?

The effectiveness of the medication, particularly in preventing pregnancy, is reliant on consistent and strict adherence to the prescribed regimen. Official research findings describe observed group outcomes, and evidence does not serve as a basis for predicting individual personal results.


Q: Is the mechanism of action of Ciclidon similar to other drugs in its class?

Ciclidon is classified as a Combined Oral Contraceptive (COC). Its primary action is similar to other COCs, functioning in the prevention of pregnancy mainly by inhibiting ovulation and causing physical changes to the cervical mucus and the lining of the uterus.


Q: What is the difference between a high-level description and a technical explanation of how Ciclidon works?

The technical explanation involves the specific steroidal components, Desogestrel and Ethinyl Estradiol, and their detailed molecular pathways. The high-level function is simpler, describing the overall effect of suppressing ovulation and modifying the reproductive tract to prevent conception.


Q: Does taking Ciclidon usually cause changes in a person's weight?

Weight gain is noted as a reported side effect in patient information. This is described alongside other common systemic effects in the official adverse reaction profiles.

How should Ciclidon be stored and disposed of?

How to Store and Dispose of Ciclidon

The storage and disposal of Ciclidon (Desogestrel and Ethinyl Estradiol tablets) must adhere strictly to regulatory requirements to ensure product stability and safety.


Storage Conditions

  • Temperature: Store at Controlled Room Temperature, typically below 30°C. Refrigeration or freezing is not required and should be avoided.
  • Protection: The medicine must be kept in the original package to protect it from light and moisture.
  • Child Safety: Ciclidon must be stored out of the sight and reach of children.

Disposal Instructions

  • Unused or expired Ciclidon and its container must be disposed of according to local pharmaceutical regulations.
  • The product must not be disposed of via wastewater or household trash to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciclidon found in:

A-Z Index: